These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21854519)

  • 21. Schering-Plough agrees to pay FDA $500 million and bring factories into compliance.
    Kuehn BM
    J Am Vet Med Assoc; 2002 Jul; 221(2):174, 180. PubMed ID: 12118571
    [No Abstract]   [Full Text] [Related]  

  • 22. Update of FDA's Critical Path Initiative.
    Khleif S
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):173-4. PubMed ID: 19398939
    [No Abstract]   [Full Text] [Related]  

  • 23. Conflict of interest in industry-sponsored drug development.
    Emanuel EJ
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):265-7. PubMed ID: 17607285
    [No Abstract]   [Full Text] [Related]  

  • 24. Big Pharma's Commedia.
    Steele FR
    Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
    [No Abstract]   [Full Text] [Related]  

  • 25. Poor reports dog industry-academia liaison.
    Nat Med; 2002 Dec; 8(12):1338-9. PubMed ID: 16437762
    [No Abstract]   [Full Text] [Related]  

  • 26. Introduction to a mini-forum on "glyconutrients".
    McClain DA
    Glycobiology; 2008 Sep; 18(9):651. PubMed ID: 18710891
    [No Abstract]   [Full Text] [Related]  

  • 27. Food and Drug Administration Modernization Act of 1997; list of documents issued by the Food and Drug Administration that apply to medical devices regulated by the Center for Biologics Evaluation and Research. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Apr; 64(79):20312-3. PubMed ID: 10558481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to Food and Drug Administration draft guidance statement on research into the treatment of life-threatening emergency conditions using exception from informed consent: testimony of the Resuscitation Outcomes Consortium.
    Ornato JP
    Acad Emerg Med; 2007 Apr; 14(4):e45-9. PubMed ID: 17400994
    [No Abstract]   [Full Text] [Related]  

  • 29. Orphan drugs of the future?
    Service RF
    Science; 2004 Mar; 303(5665):1798. PubMed ID: 15031491
    [No Abstract]   [Full Text] [Related]  

  • 30. The Investigators' Brochure: a comparison of the draft international conference on harmonisation guideline with current Food and Drug Administration requirements.
    Cocchetto DM
    Qual Assur; 1995 Dec; 4(4):240-6. PubMed ID: 8890349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug development and the FDA's Critical Path Initiative.
    Woosley RL; Cossman J
    Clin Pharmacol Ther; 2007 Jan; 81(1):129-33. PubMed ID: 17186012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
    Bramstedt KA
    Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical research--and the FDA.
    Am Fam Physician; 1978 Jul; 18(1):67-8. PubMed ID: 665475
    [No Abstract]   [Full Text] [Related]  

  • 34. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS; Mello MM
    Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Foods--adulteration involving hard or sharp foreign objects; compliance policy guide; availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Apr; 64(62):15774-5. PubMed ID: 10558459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA to clarify rules on advisory committee members.
    Tanne JH
    BMJ; 2006 Aug; 333(7562):278. PubMed ID: 16888304
    [No Abstract]   [Full Text] [Related]  

  • 37. "Guidance for Industry: For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and for the Completion of the Form FDA 356h, 'Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use;'" availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 May; 64(89):25049-50. PubMed ID: 10558535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 39. Time for new rules on human subjects research?
    Dresser R
    Hastings Cent Rep; 1998; 28(6):23-4. PubMed ID: 9868606
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-development process already subject to oversight.
    Sipkoff M
    Manag Care; 2005 Jan; 14(1):78, 80-1. PubMed ID: 15742757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.